



DATE: June 10, 2021
TO: Commonwealth of Kentucky Medicaid Pharmacy Network
FROM: MedImpact Healthcare Systems
Subject: [Kentucky Senate Bill 51, 2021 General Session](#)

Status: [Effective July 1, 2021, the following drug products will not require Prior Authorization \(PA\) for the stated type\(s\) of criteria:](#)

- **Buprenorphine-naloxone sublingual film: clinical criteria, non-preferred criteria, generic medically necessary criteria**
- **Buprenorphine sublingual tablet (generic for Subutex), Bunavail, Zubsolv, Probuphine: clinical criteria, non-preferred criteria**
- **Lucemyra: clinical criteria**

[Safety edits, as required by the Federal SUPPORT Act, will remain in effect, and most will require a PA to override.](#)

Safety edits that will require a PA to override: duplicate fill, early refill alerts, quantity limits, dosage limits, MME limits, concurrent utilization reviews for opioids and benzodiazepines, and concurrent utilization reviews for opioids and antipsychotics.

Safety edit that can be overridden by the Pharmacist: under 16 or 18 years old age edits

Please note:

- Methadone used for opioid abuse is not affected by Senate Bill 51, and is dispensed only by methadone clinics.
- Zubsolv quantity limits will be reduced from three tablets daily to two 8.6mg tablets daily and one 11.4mg tablet daily.

Contact Information: If you have any questions about the transition of PBM services for the MCOs, please contact the MedImpact Kentucky Team, beginning 07/01/2021, at:

PA Phone: 844-336-2676 KYMOCPBM@MedImpact.com <https://pharmacy.MedImpact.com>
